【活动】BioVerse: Where Science Sparks Business 13

Speaker’s Bio

David W. Shen is a well recognized expert in the Biologic drug discovery and development, and his leadership at Proteologix, Inc., a company he founded three years ago. Under his guidance, Proteologix has made significant strides in developing innovative drugs targeting immunology and inflammation diseases (I&I). The company's focus on creating highly differentiated multi-specific and multi-functional antibody drugs aims to enhance efficacy and extend molecule half-lives, thereby reducing the frequency of dosing for patients.

Recently, Proteologix's achievements culminated in its acquisition by Johnson & Johnson for a substantial $850 million, along with potential milestone payments, highlighting the value of its innovative approach in the field.

Before establishing Proteologix, David held several prominent positions, including Senior Vice President at NGM Biopharmaceuticals, Global Vice President at Teva Pharmaceuticals, and leadership roles as Biologics Department Head at Merck & Co. and Amgen. His academic credentials include a postdoctoral fellowship at the Whitehead Institute, MIT, and a PhD from the University of Toronto, laying a strong foundation for his successful career in Biotech industry. 

David is also recognized as key inventor of several groundbreaking antibody drugs, such as evolocumab (Repatha) and romosozumab (Evenity) for cardiovascular diseases and osteoporosis diseases respectively.

Kaveri Pohlman, PhD, MBA, served a Senior Analyst at BTIG where she covered small- to large-cap biotechnology companies. Prior to BTIG, Dr. Pohlman was a Postdoctoral Research Associate at Weill Cornell Medical College, where her research work focused on understanding the pathogenesis of different subtypes of prostate cancer, defining the molecular biology underlying the disease progression, and identifying new therapeutic targets. She earned a PhD in molecular and cellular biology from SUNY Downstate Medical Center, an MS in biotechnology from New York University Tandon School of Engineering, and an MBA from Birla Institute of Management Technology.

Dr. David (Xinyi) Gu is responsible for financial operations and financing strategies at EpimAb.  Previously, he was a Senior Analyst at Millennium Management covering public investments in global pharmaceutical and biotechnology companies. Before that, Dr. Gu was a Vice President and Global Pharmaceutical Equity Research Analyst at Jefferies LLC, where he was responsible for covering global large-cap pharmaceutical companies across multiple therapeutic areas. Prior to Jefferies, Dr. Gu was a management consultant at McKinsey & Company, and also held equity research positions at Wells Fargo Securities. Dr. Gu holds a Ph.D. in Pharmaceutical Sciences from the University of Michigan, and graduated summa cum laude with a Bachelor of Science degree in Biochemistry from the University of Illinois at Urbana-Champaign.